Clinical efficacy and safety of valsartan or benazepril combined with atorvastatin in the treatment of chronic cardiac failure
10.13699/j.cnki.1001-6821.2016.04.001
- VernacularTitle:缬沙坦或贝那普利联合阿托伐他汀治疗慢性心力衰竭的临床研究
- Author:
Yong-Jun HU
1
;
Shao-Yong TANG
;
Jiao CHEN
;
Qing HUANG
;
Xiong PENG
;
Ding-Feng PENG
Author Information
1. 武汉市普爱医院心内科
- Keywords:
chronic cardiac failure;
leflunomide;
glucocorticoid;
clinical efficacy;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2016;(4):291-293
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluated the clinical efficacy and safety of valsartan or benazepril combined with atorvastatin in the treatment of chronic cardiac failure in elderly patients.Methods Eighty-six cases with chronic cardiac failure were recruited in this study and randomly divided into treatment group ( n =42 ) and control group ( n =44 ).Patients in treatment group were received valsartan 80 mg · d-1 orally plus atorvastatin 10 mg · d-1 orally, patients in control group received benazepril 10 mg · d-1 orally plus atorvastatin 10 mg · d-1 orally.The course was 3 months.After treatment , the clinical efficacy , serum level of brain natriuretic peptide and adverse event were compared between the two groups.Results The total clinical efficacy of treatment group and control group were 90.48% and 86.36% respectively with no statistical difference ( P>0.05 ).The serum level of brain natriuretic peptide sig-nificant decreased in the both groups ( P<0.05 ) after treatment.And the serum level of brain natriuretic peptide in treatment group was significant lower compared with that in control group after treatment ( P<0.05 ).There were no statistical difference on adverse drug reactions between two groups ( P>0.05 ).Conclusion The clinical efficacy and safety were not significantly different for valsartan or benazepril combined with atorvastatin in the treatment of chronic cardiac failure in elderly patients .
